METHODS: A retrospective cohort study design was used and included TNBC patients treated between 2015 and 2021 at King Hussein Cancer Center. Immunohistochemistry was conducted to assess MMRP expression.
RESULTS: Among 152 patients, 14 (9.2%) exhibited deficient MMR (dMMR). Loss of PMS2 expression was observed in 13 patients, 5 of whom showed loss of MLH1 expression. Loss of MSH6 and MSH2 expression was observed in one patient. The median follow-up duration was 44 (3-102) months. Despite the higher survival rate (80.8%, 5 years) of dMMR patients than of proficient MMR patients (62.3%), overall survival did not significantly differ between the two groups.
CONCLUSIONS: Approximately 9% of TNBC patients exhibit dMMR. dMMR could be used to predict outcomes and identify patients with TNBC who may benefit from immunotherapy.
方法:采用回顾性队列研究设计,纳入2015年至2021年在侯赛因国王癌症中心接受治疗的TNBC患者。进行免疫组织化学以评估MMRP表达。
结果:在152名患者中,14(9.2%)表现出缺乏MMR(dMMR)。在13例患者中观察到PMS2表达的缺失,其中5例显示MLH1表达丧失。在一名患者中观察到MSH6和MSH2表达的缺失。中位随访时间为44(3-102)个月。尽管存活率较高(80.8%,5年)的DMMR患者比熟练的MMR患者(62.3%),两组的总生存期无显著差异.
结论:大约9%的TNBC患者表现出dMMR。dMMR可用于预测结果和确定可能受益于免疫治疗的TNBC患者。